"Cancer Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
| Descriptor ID |
D019496
|
| MeSH Number(s) |
D20.215.894.200
|
| Concept/Terms |
Cancer Vaccines- Cancer Vaccines
- Vaccines, Tumor
- Vaccines, Neoplasm
- Tumor Vaccines
- Vaccines, Cancer
- Neoplasm Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Cancer Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Cancer Vaccines".
This graph shows the total number of publications written about "Cancer Vaccines" by people in this website by year, and whether "Cancer Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 3 | 2 | 5 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 2 | 3 |
| 2001 | 4 | 1 | 5 |
| 2002 | 5 | 1 | 6 |
| 2003 | 3 | 4 | 7 |
| 2004 | 2 | 1 | 3 |
| 2005 | 4 | 0 | 4 |
| 2006 | 4 | 0 | 4 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 2 | 4 |
| 2009 | 5 | 3 | 8 |
| 2010 | 10 | 1 | 11 |
| 2011 | 6 | 2 | 8 |
| 2012 | 4 | 2 | 6 |
| 2013 | 3 | 1 | 4 |
| 2014 | 8 | 5 | 13 |
| 2015 | 1 | 1 | 2 |
| 2016 | 3 | 2 | 5 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 9 | 2 | 11 |
| 2020 | 7 | 3 | 10 |
| 2021 | 4 | 1 | 5 |
| 2022 | 2 | 0 | 2 |
| 2023 | 3 | 0 | 3 |
| 2024 | 2 | 1 | 3 |
| 2025 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cancer Vaccines" by people in Profiles.
-
Nanoplasmid PSMA DNA vaccine primes antitumor immunity and enhances response to PD-1 blockade against prostate cancer. Cancer Lett. 2026 Sep 01; 655:218591.
-
Serum Arginase-1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness. Oncoimmunology. 2025 Dec 31; 14(1):2595764.
-
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025 11; 647(8089):488-497.
-
Translational advancement of immunotherapeutics against pediatric central nervous system tumors. Adv Cancer Res. 2025; 167:327-358.
-
The promise of immunotherapy for central nervous system tumours. Nat Rev Immunol. 2026 Mar; 26(3):213-229.
-
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival. Hum Vaccin Immunother. 2025 Dec; 21(1):2556591.
-
IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines. Proc Natl Acad Sci U S A. 2024 11 26; 121(48):e2322356121.
-
Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep. 2024 11 26; 43(11):114875.
-
Durable lymph-node expansion is associated with the efficacy of therapeutic vaccination. Nat Biomed Eng. 2024 10; 8(10):1226-1242.
-
Stereoselective Synthesis of Sialyl Lewisa Antigen and the Effective Anticancer Activity of Its Bacteriophage Q? Conjugate as an Anticancer Vaccine. Angew Chem Int Ed Engl. 2023 11 20; 62(47):e202309744.